In our current work, we show that Carfilzomib, and other proteasomal inhibitors to a lesser degree, reprogrammed M2 into M1‐like macrophages, such that more CD8+ T cells infiltrated and controlled tumor in vivo. The gene discussed is CD8A; the disease is neoplasm.